Company Encyclopedia
View More
name
Arcturus Therapeutics
ARCT.US
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis.
1.946 T
ARCT.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking250/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-27.43%E
    • Profit Margin-68.35%E
    • Gross Margin80.51%A
  • Growth ScoreE
    • Revenue YoY-39.15%E
    • Net Profit YoY-6.49%C
    • Total Assets YoY-23.83%E
    • Net Assets YoY-14.25%E
  • Cash ScoreE
    • Cash Flow Margin-146.31%D
    • OCF YoY-39.15%E
  • Operating ScoreD
    • Turnover0.3D
  • Debt ScoreA
    • Gearing Ratio20.47%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Arcturus Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

    Arcturus Therapeutics Holdings Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference with a fireside chat on December 2, 2025, at 12:30 p.m. ET. This information was originally published by Arcturus Therapeutics via Business Wire.

    Reuters·
    US
    ARCT
    +3.64%
    Reuters·
    US
    ARCT
    +3.64%

    Arcturus Therapeutics (NASDAQ:ARCT) Given New $72.00 Price Target at Piper Sandler

    Piper Sandler has lowered its price target for Arcturus Therapeutics (NASDAQ:ARCT) from $140.00 to $72.00, maintaining an "overweight" rating. Other analysts have also downgraded the stock, with a consensus rating of "Moderate Buy" and a target price of $36.38. The stock traded down to $8.72, with a market cap of $236.66 million. Arcturus reported a quarterly EPS of ($0.49), beating estimates, but had a negative net margin of 49.26%. Institutional investors hold 94.54% of the stock.

    Market Beat·
    US
    ARCT
    +3.64%
    Market Beat·
    US
    ARCT
    +3.64%

    HC Wainwright Lowers Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $9.00

    HC Wainwright has lowered its price target for Arcturus Therapeutics (NASDAQ:ARCT) from $12.00 to $9.00, maintaining a "neutral" rating. This suggests a potential upside of 3.21% from the current price of $8.72. Other analysts have also adjusted their ratings, with Wells Fargo reducing its target to $20.00 and Guggenheim downgrading to "neutral." The average rating for ARCT is currently "Hold" with a target of $31.29. The stock has seen a decline of 0.7% recently, with a market cap of $236.79 million and a negative net margin of 49.26%.

    Market Beat·
    US
    ARCT
    +3.64%
    Market Beat·
    US
    ARCT
    +3.64%

    Arcturus Therapeutics: Promising Developments and Strong Financial Position Justify Buy Rating

    Analyst Thomas Shrader of BTIG has maintained a Buy rating on Arcturus Therapeutics with a price target of $23.00, citing the company's promising ARCT-032 program for cystic fibrosis and strong financial position. The program has received positive feedback, leading to a new trial planned for Type 1 patients. Arcturus ended Q3 with $237.3 million in cash, ensuring financial stability until 2028. The company's innovative SAM-RNA vaccine platform also addresses safety concerns, contributing to a positive outlook and justifying the Buy rating.

    Tip Ranks·
    US
    ARCT
    +3.64%
    Tip Ranks·
    US
    ARCT
    +3.64%

    Arcturus Therapeutics | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 17.15 M

    LB filings·
    US
    ARCT
    +3.64%
    LB filings·
    US
    ARCT
    +3.64%
    © 2025 Longbridge｜Disclaimer